MHRA updates Guidance on Sourcing Medicines for the UK Market
Recommendation
21/22 May 2025
Munich, Germany
Register now for ECA's GMP Newsletter
The UK Medicines & Healthcare Products Regulatory Agency (MHRA) has updated its guidance on sourcing medicines for the UK market.
The document, which was first published on 31 December 2020, provides information on sourcing medicines that can be supplied by holders of wholesale distributor authorisations (WDAs) based in the UK.
The guidance covers the following aspects:
- Importing authorised medicines into the UK from a source which is on the approved country for import list
- Importing human medicines from a country on the list – for use as a special medicinal product
- Procuring human medicines from a country on the list for export purposes
- Importing medicines from a country on the list for supply to the United Kingdom parallel import market
The latest updates, published on 30 December 2024, reflect the new UK-wide licensing arrangements for human medicines that came into effect from 01 January 2025 as part of the Windsor Framework.
The complete guidance is available on the MHRA website.
Related GMP News
15.04.2025Falsified Medicinal Products: Swissmedic Intensifies Controls on International Trade
15.04.2025EMA's 3-Year Work Plan for GMDP Inspectors Working Group: What's Planned for GDP?
15.04.2025MHRA Class 2 Recall due to Blister Pack Mislabeling
15.04.2025Two GDP Non-Compliance Reports published in March
15.04.2025Visit the DHL Vienna Airport Campus
15.04.2025Questions and Answers from the ECA Webinar "GDP Update 2025" - Part 1